Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Am J Ophthalmol. 2016 Aug 12;170:206–213. doi: 10.1016/j.ajo.2016.08.008

Figure 2.

Figure 2

Treatment group differences, adjusted for baseline score and optical coherence tomography (OCT) central subfield thickness, between the ranibizumab and PRP groups for the change from baseline in the University of Alabama at Birmingham Low Luminance Questionnaire (UAB-LLQ) composite score and subscales at the 1-year (Left) and 2-year visits (Right). Whiskers represent the 95% confidence interval for the composite score (black square) or 99% confidence intervals for the subscales (gray circles). Values above the dashed line favor the ranibizumab group while values below the dashed line favor the PRP group.